



**TELECONFERENCE/VIRTUAL
CONTROLLED SUBSTANCES BOARD
Room N208, 4822 Madison Yards Way, 2nd Floor, Madison
Contact: Erin Karow (608) 266-2112
October 9, 2018**

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

2:00 P.M.

OPEN SESSION - CALL TO ORDER – ROLL CALL

A. Adoption of Agenda (1-2)

B. Administrative Matters - Discussion and Consideration

1. Staff Updates
2. Board Members
 - a. Yvonne Bellay – Dept. of Agriculture, Trade, and Consumer Protection Designee
 - b. Alan Bloom – Pharmacologist
 - c. Doug Englebert – Dept. of Health Services Designee
 - d. Philip Trapskin – Pharmacy Examining Board Designee
 - e. Subhadeep Barman – Psychiatrist
 - f. Peter Kallio – Board of Nursing Designee
 - g. Leonardo Huck – Dentistry Examining Board Designee
 - h. Tina Virgil – Attorney General Designee
 - i. Timothy Westlake – Medical Examining Board Designee

C. Legislation and Administrative Rule Matters – Discussion and Consideration (3)

1. Scheduling of Epidiolex
2. Approval of Pharmacies and Physicians to Dispense FDA Approved Cannabidiol
3. Update on Legislation and Pending and Possible Rulemaking Projects

D. Public Comments

ADJOURNMENT

NEXT MEETING: NOVEMBER 9, 2018

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED
WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held at 4822 Madison Yards Way, Madison, Wisconsin, unless otherwise noted. In order to confirm a meeting or to request a complete copy of the board's agenda, please call the listed contact person. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Interpreters for the hearing impaired provided upon request by contacting the Affirmative Action Officer, 608-266-2112.

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On September 28, 2018, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register placing U.S. Food and Drug Administration approved cannabidiol drugs into schedule V of the federal Controlled Substances Act. The scheduling action is effective September 28, 2018.
2. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.21 and omitting the notice of proposed rule-making, designating U.S. Food and Drug Administration approved cannabidiol drugs as a schedule V controlled substances.

ORDER

Pursuant to s. 961.11(4g), Stats., the Controlled Substances Board by affirmative action similarly treats cannabidiol drugs under chapter 961, Stats. by creating the following:

CSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section 961.22 (7), Stats., is created to read:

961.22 (7) APPROVED CANNABIDIOL DRUGS. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.

This order shall take effect on October 15, 2018 to allow for publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated _____

Doug Englebert, Chair
Controlled Substances Board